Abstract
In response to the coronavirus disease 2019 (COVID-19) pandemic, a direct e-mail to American Academy of Ophthalmology membership urged “that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately.”1 In the United States, the Academy’s Intelligent Research in Sight (IRIS®) Registry represents one of the largest and most advanced registry databases: more than 70% of United States ophthalmologists contribute to the IRIS Registry database.2 We used the IRIS Registry to study the treatment of common ophthalmic conditions before and after the Academy’s letter, specifically for those receiving intravitreal injections of anti–vascular endothelial growth factor (VEGF) agents to stabilize and improve vision.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
